Nature Reviews Clinical Oncology - Table of Contents alert Volume 14 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2017 Volume 14 Number 2
2015 2-year Impact Factor 18.786 Journal Metrics 2-year Median 11	In this issue Editorial Research Highlights Year in Review Reviews Correspondence Erratum Perspectives Also this month  Featured article: Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Adi J. Klil-Drori, Laurent Azoulay & Michael N. Pollak
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation. Now open for submissions >>
EDITORIAL		Top
Key advances: translation and location Published online: 23 January 2017 p67 | doi:10.1038/nrclinonc.2017.7 Full Text | PDF
RESEARCH HIGHLIGHTS Top Lung cancer: AURA3 magic reveals new standard Published online: 29 December 2016 p69 | doi:10.1038/nrclinonc.2016.220 PDF Liver cancer: Regorafenib — a new RESORCE in HCC Published online: 20 December 2016 p70 | doi:10.1038/nrclinonc.2016.214 PDF Immunotherapy: Benefit with anti-PD-L1 Published online: 29 December 2016 p70 | doi:10.1038/nrclinonc.2016.218 PDF Gynaecological cancer: PARP inhibition — moving beyond BRCA-mutated disease Published online: 13 December 2016 p71 | doi:10.1038/nrclinonc.2016.207 PDF In the news: From ENA 2016 Published online: 20 December 2016 p72 | doi:10.1038/nrclinonc.2016.213 PDF Haematological cancer: TP53 mutations sensitize to decitabine Published online: 20 December 2016 p72 | doi:10.1038/nrclinonc.2016.215 PDF Lung cancer: ET — platinum therapy comes home Published online: 29 December 2016 p72 | doi:10.1038/nrclinonc.2016.216 PDF IN BRIEF Targeted therapy: Sunitinib modulates MCL-1 and mTOR signalling | Imaging: Solid stress indicates tumour pathology | Haematological cancer: Rituximab enhances responses to lenalidomide PDF Nature Reviews Clinical Oncology JOBS of the week Sr. Scientist - Center for Immuno-Oncology (path lab) Dana-Farber Cancer Institute (DFCI) Radiation Oncology Research Faculty, NYU Langone School of Medicine NYU Langone Medical Center Laboratory Investigator Division of Hematologic Neoplasia Dana-Farber Cancer Institute (DFCI) Tenure-Track Faculty Positions University of Pennsylvania Sr. Scientist - Center for Immuno-Oncology (path lab) Dana-Farber Cancer Institute (DFCI) More Science jobs from Nature Reviews Clinical Oncology EVENT Quantitative Approaches in Immuno-Oncology 01.03.17 New York, USA More science events from
YEAR IN REVIEW		Top
Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity Prashant Kapoor & S. Vincent Rajkumar Published online: 10 January 2017 p73 | doi:10.1038/nrclinonc.2016.221 Data obtained in the past year underscored the benefit of a triplet regimen comprising bortezomib, lenalidomide, and dexamethasone for patients with newly-diagnosed multiple myeloma, and have provided high-level evidence supporting the safety of adding daratumumab to standard-of-care doublets for those with relapsed and/or refractory disease. As a result, achieving minimal residual disease-negativity at any stage of myeloma is now a realistic possibility. Full Text | PDF
Small-cell lung cancer in 2016: Shining light on novel targets and therapies Charles M. Rudin & John T. Poirier Published online: 13 December 2016 p75 | doi:10.1038/nrclinonc.2016.203 In 2016, the pace of biological insights into small-cell lung cancer (SCLC) was reflected in new treatment approaches that have suggested meaningful clinical benefit to patients. We focus on three highlights of 2016: preclinical studies defining NFIB as a putative driver of metastasis, and two clinical studies; one that assessed the efficacy of an agent targeting the Notch ligand DLL3, and the other that explored T-cell checkpoint-blockade therapies targeting PD-1 and CTLA-4. Full Text | PDF
Head and neck cancer in 2016: A watershed year for improvements in treatment? Alain P. Algazi & Jennifer R. Grandis Published online: 06 December 2016 p76 | doi:10.1038/nrclinonc.2016.196 In the past year, clinical trials have provided important information on strategies to decrease treatment-associated toxicities in patients with head and neck cancer. In addition, the FDA approved the first immunotherapeutic agents for patients with recurrent and/or metastatic disease, based on the observation of durable responses to pembrolizumab in a phase Ib trial, and demonstration of improved survival and quality of life with the use of nivolumab versus chemotherapy in a phase III trial. Full Text | PDF
Sarcoma in 2016: Evolving biological understanding and treatment of sarcomas Jean-Yves Blay & Isabelle Ray-Coquard Published online: 13 December 2016 p78 | doi:10.1038/nrclinonc.2016.200 In 2016, novel findings on the role of predisposing gene variants in sarcoma oncogenesis were published, as well as studies addressing novel molecular classifications and results from randomized controlled trials highlighting successful new treatments. Herein, we discuss these meaningful advances. Full Text | PDF
Neuroendocrine tumours in 2016: Defining rules for increasingly personalized treatments Massimo Falconi & Stefano Partelli Published online: 06 December 2016 p80 | doi:10.1038/nrclinonc.2016.197 In 2016, results of an extensive trial broadened the range of malignancies that can be treated with everolimus to include neuroendocrine tumours (NETs) of the lung and gastrointestinal tract. Furthermore, studies aimed at identifying biomarkers with increased specificity, and at better defining high-grade NETs have enabled substantial progress towards delivering effective targeted treatments to patients with NETs. Full Text | PDF
Renal-cell carcinoma in 2016: Advances in treatment — jostling for pole position Laurence Albiges & Toni K. Choueiri Published online: 10 January 2017 p82 | doi:10.1038/nrclinonc.2016.224 In 2016, two major trials provided conflicting evidence regarding the role of 1 year of adjuvant therapy with sunitinib for patients with high-risk renal-cell carcinoma. In the second-line metastatic setting, updated data from key trials showed that cabozantinib improved overall survival over everolimus, and nivolumab was associated with a better quality of life compared with everolimus. Finally, a phase II study in previously untreated patients showed cabozantinib to be superior to sunitinib. Full Text | PDF
REVIEWS		Top
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Adi J. Klil-Drori, Laurent Azoulay & Michael N. Pollak Published online: 09 August 2016 p85 | doi:10.1038/nrclinonc.2016.120 The prevalence rates of obesity, type 2 diabetes mellitus, and cancer are increasing globally. Herein, the relationships between these diseases and their treatments are reviewed, and the practical principles relevant to the increasingly common challenge of managing patients who have been diagnosed with both diabetes and cancer are outlined. Abstract | Full Text | PDF
Genomic complexity of multiple myeloma and its clinical implications Salomon Manier et al. Published online: 17 August 2016 p100 | doi:10.1038/nrclinonc.2016.122 In the past 5 years, results from large-scale whole-exome sequencing studies have brought new insight into the clonal heterogeneity and evolution of multiple myeloma, a genetically complex disease. Herein, the authors describe the driver gene alterations and sequential acquisition of the main genomic aberrations involved in this disease, with a focus on the clonal heterogeneity of multiple myeloma and its clinical implications. Abstract | Full Text | PDF
CORRESPONDENCE		Top
First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm Chiara Cremolini et al. Published online: 17 January 2017 p113 | doi:10.1038/nrclinonc.2016.219 Full Text | PDF | Supplementary information
ERRATUM		Top
Erratum: Cancer metabolism: a therapeutic perspective Ubaldo E. Martinez-Outschoorn et al. Published online: 17 January 2017 p113 | doi:10.1038/nrclinonc.2017.1 Full Text | PDF
PERSPECTIVES		Top
OPINION A second chance for telomerase reverse transcriptase in anticancer immunotherapy Maurizio Zanetti Published online: 01 June 2016 p115 | doi:10.1038/nrclinonc.2016.67 Telomerase reverse transcriptase (TERT) is expressed constitutively in tumour cells throughout the evolution of many cancers; therefore, this potential tumour self-antigen has been an important target for anticancer vaccines over the past 10 years, but only modest benefits from this approach have been observed in clinical trials. In this Perspectives, Maurizio Zanetti reviews these studies, and highlights advances in our knowledge that warrant further development and refinement of TERT immunotherapy. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.